Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319292 | 0.77 | SMYD2 (0.32) | SMYD2CYP3A4HTTSMN1; SMN2GRM5 | |
| SCHEMBL20972538 | 0.77 | KCNH2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2GRM5 | |
| SCHEMBL30825711 | 0.76 | SYK (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8709966 | 0.76 | SYK (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1314001 | 0.75 | AGXT (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1181594 | 0.75 | ATM (0.35) | GABRA5CYP3A4HTTSMN1; SMN2GRM5 | |
| SCHEMBL2598798 | 0.74 | LTA4H (0.41) | SMYD2HTTSMN1; SMN2GRM5GRM1 | |
| SCHEMBL3421369 | 0.74 | CHRM2 (0.53) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL16319196 | 0.73 | BACE1 (0.34) | GABRA5SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4150467 | 0.73 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | GABRA1 4629/4885GABRG2 4684/4885GABRB3 4705/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | GABRA1 4629/4885GABRG2 4684/4885GABRB3 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.